Subcutaneous Immunoglobulin (SCIG)
Primary Immunodeficiencies
Key Facts
About Shanghai RAAS Blood Products
Shanghai RAAS's mission is to ensure a stable, safe, and sufficient supply of plasma-derived therapeutics for the Chinese market, serving as a cornerstone of national biosecurity. The company has achieved a leading market position through strategic vertical integration, operating one of the largest networks of plasma collection stations and state-of-the-art fractionation facilities in the country. Its strategy is anchored in scaling plasma collection, expanding its high-value product portfolio (particularly immunoglobulins and factor concentrates), and maintaining technological leadership in viral safety and yield optimization. RAAS is poised for sustained growth driven by rising clinical demand, favorable reimbursement policies, and China's strategic push for plasma product self-sufficiency.
View full company profileAbout Grifols
Grifols is a century-old global leader in plasma-derived medicines and diagnostics, operating across four core divisions: Biopharma, Diagnostics, Bio Supplies, and Hospital Healthcare Solutions. Its mission to improve health is powered by deep plasma science expertise, a robust manufacturing footprint, and significant industry recognition, including repeated honors from TIME and Forbes. The company's strategy focuses on vertical integration in plasma, geographic expansion, and scientific innovation, including exploring new therapeutic areas like neurology through its CHRONOS-PD platform.
View full company profileTherapeutic Areas
Other Primary Immunodeficiencies Drugs
| Drug | Company | Phase |
|---|---|---|
| Immunoglobulin (SCIG) | Kedrion Biopharma | Phase 3 / Registration |
| HyQvia® (with Takeda) | Halozyme Therapeutics | Approved |